Retigabine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Retigabine" in English language version.

refsWebsite

Global rank English rank

18nih.gov

4^th place

12doi.org

2^nd place

5semanticscholar.org

11^th place

8^th place

5web.archive.org

1^st place

2epilepsysociety.org.uk

low place

2fda.gov

447^th place

338^th place

2medscape.com

719^th place

636^th place

2drugs.com

399^th place

333^rd place

2ama-assn.org

3,257^th place

3,398^th place

1gsksource.com

low place

1publishing.service.gov.uk

1,877^th place

1,129^th place

1neurologylive.com

low place

1medicines.org.uk

3,823^rd place

2,387^th place

1gpo.gov

1,360^th place

845^th place

1who.int

195^th place

302^nd place

ama-assn.org (Global: 3,257^th place; English: 3,398^th place)

[No authors listed] (2005–2006). "Statement on a nonproprietary name adopted by the USAN council: Retigabine" (PDF). American Medical Association. Retrieved 2010-07-19.
[No authors listed] (2010). "Statement on a nonproprietary name adopted by the USAN council: Ezogabine" (PDF). American Medical Association. Archived from the original (PDF) on 2012-04-02. Retrieved 2010-07-19.

doi.org (Global: 2^nd place; English: 2^nd place)

Ferron GM, Paul J, Fruncillo R, Richards L, Knebel N, Getsy J, Troy S (February 2002). "Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers". Journal of Clinical Pharmacology. 42 (2): 175–182. doi:10.1177/00912700222011210. PMID 11831540. S2CID 5568963.
Rundfeldt C (October 1997). "The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells". European Journal of Pharmacology. 336 (2–3): 243–249. doi:10.1016/S0014-2999(97)01249-1. PMID 9384239.
Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA (August 2000). "Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine". Molecular Pharmacology. 58 (2): 253–262. doi:10.1124/mol.58.2.253. PMID 10908292. S2CID 11112809.
Rogawski MA, Bazil CW (July 2008). "New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels". Current Neurology and Neuroscience Reports. 8 (4): 345–352. doi:10.1007/s11910-008-0053-7. PMC 2587091. PMID 18590620.
Ben-Menachem E (2007). "Retigabine: has the orphan found a home?". Epilepsy Currents. 7 (6): 153–154. doi:10.1111/j.1535-7511.2007.00209.x. PMC 2096728. PMID 18049722.
Plosker GL, Scott LJ (2006). "Retigabine: in partial seizures". CNS Drugs. 20 (7): 601–8, discussion 609–10. doi:10.2165/00023210-200620070-00005. PMID 16800718. S2CID 23557118.
Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM (April 2007). "Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures". Neurology. 68 (15): 1197–1204. doi:10.1212/01.wnl.0000259034.45049.00. PMID 17420403. S2CID 24574886.
Luszczki JJ (2009). "Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions". Pharmacological Reports. 61 (2): 197–216. doi:10.1016/s1734-1140(09)70024-6. PMID 19443931. S2CID 72918370.
Brown DA, Passmore GM (April 2009). "Neural KCNQ (Kv7) channels". British Journal of Pharmacology. 156 (8): 1185–1195. doi:10.1111/j.1476-5381.2009.00111.x. PMC 2697739. PMID 19298256.
Corbin-Leftwich A, Mossadeq SM, Ha J, Ruchala I, Le AH, Villalba-Galea CA (March 2016). "Retigabine holds KV7 channels open and stabilizes the resting potential". The Journal of General Physiology. 147 (3): 229–241. doi:10.1085/jgp.201511517. PMC 4772374. PMID 26880756.
Villalba-Galea CA (2020-06-19). "Modulation of K_V7 Channel Deactivation by PI(4,5)P₂". Frontiers in Pharmacology. 11: 895. doi:10.3389/fphar.2020.00895. PMC 7318307. PMID 32636742.
Rogawski MA (June 2006). "Diverse mechanisms of antiepileptic drugs in the development pipeline". Epilepsy Research. 69 (3): 273–294. doi:10.1016/j.eplepsyres.2006.02.004. PMC 1562526. PMID 16621450.

drugs.com (Global: 399^th place; English: 333^rd place)

"Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN)" (Press release). PRNewswire. 2009-08-24. Retrieved 2011-06-13.
"Retigabine NDA accepted for filing" (Press release). PRNewswire. 2009-12-30. Retrieved 2010-07-19.

epilepsysociety.org.uk (Global: low place; English: low place)

"Epilepsy drug Trobalt (retigabine) to be discontinued". epilepsysociety.org.uk. 14 September 2016.
"Epilepsy drug Trobalt (retigabine) to be discontinued | Epilepsy Society". epilepsysociety.org.uk. 2016-09-14. Retrieved 2025-12-19.

fda.gov (Global: 447^th place; English: 338^th place)

"Potiga (Ezogabine): Drug Safety Communication". Food and Drug Administration. Archived from the original on April 29, 2013.
[No authors listed] (2010-06-25). "August 11, 2010: Peripheral and Central Nervous System Drugs Advisory Committee Meeting Announcement". U.S. Food and Drug Administration. Archived from the original on July 3, 2010. Retrieved 2010-07-19.

gpo.gov (Global: 1,360^th place; English: 845^th place)

U.S. Drug Enforcement Administration (15 December 2011). "Schedules of Controlled Substances: Placement of Ezogabine Into Schedule V" (PDF). Federal Register. 76 (241).

gsksource.com (Global: low place; English: low place)

"POTIGA (ezogabine) Tablets, CV. Full Prescribing Information" (PDF). GlaxoSmithKline and Valeant Pharmaceuticals. Retrieved 4 June 2014.

medicines.org.uk (Global: 3,823^rd place; English: 2,387^th place)

"Trobalt – Summary of Product Characteristics (SPC)". electronic Medicines Compendium. 2011-05-05. Retrieved 2011-06-13.

medscape.com (Global: 719^th place; English: 636^th place)

Hitt E (2011-06-13). "FDA approves ezogabine for seizures in adults". Medscape. Retrieved 2011-06-13.
Lowry F (2010-08-12). "Epilepsy drug exogabine gets green light from FDA Advisory Panel". Medscape. Retrieved 2010-08-13.

neurologylive.com (Global: low place; English: low place)

MD, Veronica Hackethal (2025-12-19). "Anticonvulsant Potiga Discontinued in June 2017 | NeurologyLive - Clinical Neurology News and Neurology Expert Insights". www.neurologylive.com. Retrieved 2025-12-19.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Ferron GM, Paul J, Fruncillo R, Richards L, Knebel N, Getsy J, Troy S (February 2002). "Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers". Journal of Clinical Pharmacology. 42 (2): 175–182. doi:10.1177/00912700222011210. PMID 11831540. S2CID 5568963.
Rundfeldt C (October 1997). "The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells". European Journal of Pharmacology. 336 (2–3): 243–249. doi:10.1016/S0014-2999(97)01249-1. PMID 9384239.
Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA (August 2000). "Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine". Molecular Pharmacology. 58 (2): 253–262. doi:10.1124/mol.58.2.253. PMID 10908292. S2CID 11112809.
Rogawski MA, Bazil CW (July 2008). "New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels". Current Neurology and Neuroscience Reports. 8 (4): 345–352. doi:10.1007/s11910-008-0053-7. PMC 2587091. PMID 18590620.
Ben-Menachem E (2007). "Retigabine: has the orphan found a home?". Epilepsy Currents. 7 (6): 153–154. doi:10.1111/j.1535-7511.2007.00209.x. PMC 2096728. PMID 18049722.
Plosker GL, Scott LJ (2006). "Retigabine: in partial seizures". CNS Drugs. 20 (7): 601–8, discussion 609–10. doi:10.2165/00023210-200620070-00005. PMID 16800718. S2CID 23557118.
Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM (April 2007). "Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures". Neurology. 68 (15): 1197–1204. doi:10.1212/01.wnl.0000259034.45049.00. PMID 17420403. S2CID 24574886.
Luszczki JJ (2009). "Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions". Pharmacological Reports. 61 (2): 197–216. doi:10.1016/s1734-1140(09)70024-6. PMID 19443931. S2CID 72918370.
Brown DA, Passmore GM (April 2009). "Neural KCNQ (Kv7) channels". British Journal of Pharmacology. 156 (8): 1185–1195. doi:10.1111/j.1476-5381.2009.00111.x. PMC 2697739. PMID 19298256.
Corbin-Leftwich A, Mossadeq SM, Ha J, Ruchala I, Le AH, Villalba-Galea CA (March 2016). "Retigabine holds KV7 channels open and stabilizes the resting potential". The Journal of General Physiology. 147 (3): 229–241. doi:10.1085/jgp.201511517. PMC 4772374. PMID 26880756.
Villalba-Galea CA (2020-06-19). "Modulation of K_V7 Channel Deactivation by PI(4,5)P₂". Frontiers in Pharmacology. 11: 895. doi:10.3389/fphar.2020.00895. PMC 7318307. PMID 32636742.
Rogawski MA (June 2006). "Diverse mechanisms of antiepileptic drugs in the development pipeline". Epilepsy Research. 69 (3): 273–294. doi:10.1016/j.eplepsyres.2006.02.004. PMC 1562526. PMID 16621450.

ncbi.nlm.nih.gov

Rogawski MA, Bazil CW (July 2008). "New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels". Current Neurology and Neuroscience Reports. 8 (4): 345–352. doi:10.1007/s11910-008-0053-7. PMC 2587091. PMID 18590620.
Ben-Menachem E (2007). "Retigabine: has the orphan found a home?". Epilepsy Currents. 7 (6): 153–154. doi:10.1111/j.1535-7511.2007.00209.x. PMC 2096728. PMID 18049722.
Brown DA, Passmore GM (April 2009). "Neural KCNQ (Kv7) channels". British Journal of Pharmacology. 156 (8): 1185–1195. doi:10.1111/j.1476-5381.2009.00111.x. PMC 2697739. PMID 19298256.
Corbin-Leftwich A, Mossadeq SM, Ha J, Ruchala I, Le AH, Villalba-Galea CA (March 2016). "Retigabine holds KV7 channels open and stabilizes the resting potential". The Journal of General Physiology. 147 (3): 229–241. doi:10.1085/jgp.201511517. PMC 4772374. PMID 26880756.
Villalba-Galea CA (2020-06-19). "Modulation of K_V7 Channel Deactivation by PI(4,5)P₂". Frontiers in Pharmacology. 11: 895. doi:10.3389/fphar.2020.00895. PMC 7318307. PMID 32636742.
Rogawski MA (June 2006). "Diverse mechanisms of antiepileptic drugs in the development pipeline". Epilepsy Research. 69 (3): 273–294. doi:10.1016/j.eplepsyres.2006.02.004. PMC 1562526. PMID 16621450.

publishing.service.gov.uk (Global: 1,877^th place; English: 1,129^th place)

assets.publishing.service.gov.uk

"GlaxoSmithKline: Advance notification of trobalt discontinuation" (PDF). Archived from the original (PDF) on 2016-10-19.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Ferron GM, Paul J, Fruncillo R, Richards L, Knebel N, Getsy J, Troy S (February 2002). "Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers". Journal of Clinical Pharmacology. 42 (2): 175–182. doi:10.1177/00912700222011210. PMID 11831540. S2CID 5568963.
Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA (August 2000). "Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine". Molecular Pharmacology. 58 (2): 253–262. doi:10.1124/mol.58.2.253. PMID 10908292. S2CID 11112809.
Plosker GL, Scott LJ (2006). "Retigabine: in partial seizures". CNS Drugs. 20 (7): 601–8, discussion 609–10. doi:10.2165/00023210-200620070-00005. PMID 16800718. S2CID 23557118.
Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM (April 2007). "Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures". Neurology. 68 (15): 1197–1204. doi:10.1212/01.wnl.0000259034.45049.00. PMID 17420403. S2CID 24574886.
Luszczki JJ (2009). "Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions". Pharmacological Reports. 61 (2): 197–216. doi:10.1016/s1734-1140(09)70024-6. PMID 19443931. S2CID 72918370.

web.archive.org (Global: 1^st place; English: 1^st place)

"GlaxoSmithKline: Advance notification of trobalt discontinuation" (PDF). Archived from the original (PDF) on 2016-10-19.
"Potiga (Ezogabine): Drug Safety Communication". Food and Drug Administration. Archived from the original on April 29, 2013.
[No authors listed] (2010-06-25). "August 11, 2010: Peripheral and Central Nervous System Drugs Advisory Committee Meeting Announcement". U.S. Food and Drug Administration. Archived from the original on July 3, 2010. Retrieved 2010-07-19.
World Health Organization (1996). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 76" (PDF). WHO Drug Information. 10 (4): 215. Archived from the original (PDF) on June 27, 2004.
[No authors listed] (2010). "Statement on a nonproprietary name adopted by the USAN council: Ezogabine" (PDF). American Medical Association. Archived from the original (PDF) on 2012-04-02. Retrieved 2010-07-19.

who.int (Global: 195^th place; English: 302^nd place)

whqlibdoc.who.int

World Health Organization (1996). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 76" (PDF). WHO Drug Information. 10 (4): 215. Archived from the original (PDF) on June 27, 2004.

Retigabine (English Wikipedia)

ama-assn.org (Global: 3,257th place; English: 3,398th place)

doi.org (Global: 2nd place; English: 2nd place)

drugs.com (Global: 399th place; English: 333rd place)

epilepsysociety.org.uk (Global: low place; English: low place)

fda.gov (Global: 447th place; English: 338th place)

gpo.gov (Global: 1,360th place; English: 845th place)

gsksource.com (Global: low place; English: low place)

medicines.org.uk (Global: 3,823rd place; English: 2,387th place)

medscape.com (Global: 719th place; English: 636th place)

neurologylive.com (Global: low place; English: low place)

nih.gov (Global: 4th place; English: 4th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

publishing.service.gov.uk (Global: 1,877th place; English: 1,129th place)

assets.publishing.service.gov.uk

semanticscholar.org (Global: 11th place; English: 8th place)

api.semanticscholar.org

web.archive.org (Global: 1st place; English: 1st place)

who.int (Global: 195th place; English: 302nd place)

whqlibdoc.who.int

ama-assn.org (Global: 3,257^th place; English: 3,398^th place)

doi.org (Global: 2^nd place; English: 2^nd place)

drugs.com (Global: 399^th place; English: 333^rd place)

fda.gov (Global: 447^th place; English: 338^th place)

gpo.gov (Global: 1,360^th place; English: 845^th place)

medicines.org.uk (Global: 3,823^rd place; English: 2,387^th place)

medscape.com (Global: 719^th place; English: 636^th place)

nih.gov (Global: 4^th place; English: 4^th place)

publishing.service.gov.uk (Global: 1,877^th place; English: 1,129^th place)

semanticscholar.org (Global: 11^th place; English: 8^th place)

web.archive.org (Global: 1^st place; English: 1^st place)

who.int (Global: 195^th place; English: 302^nd place)